91°µÍø

Skip to main content

All News

ORNL's Communications team works with news media seeking information about the laboratory. Media may use the resources listed below or send questions to news@ornl.gov.

1 - 10 of 14 Results

dog

After retiring from Y-12, Scott Abston joined the Isotope Science and Engineering Directorate to support isotope production and work with his former manager. He now leads a team maintaining critical equipment for medical and space applications. Abston finds fulfillment in mentoring his team and is pleased with his decision to continue working.

Symposium guests view posters in the poster competition. Credit: Laetitia Delmau/ORNL, U.S. Dept. of Energy

The 21st Symposium on Separation Science and Technology for Energy Applications, Oct. 23-26 at the Embassy Suites by Hilton West in Knoxville, attracted 109 researchers, including some from Austria and the Czech Republic. Besides attending many technical sessions, they had the opportunity to tour the Graphite Reactor, High Flux Isotope Reactor and both supercomputers at ORNL.

Radiochemist Shelley VanCleve works to purify an isotope using a glove box in ORNL’s Radiochemical Engineering Development Center. VanCleve was involved in the final purification of berkelium that led to the discovery of the new element 117, tennessine, in 2010. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

It’s elemental — scientists agree that the periodic table is incomplete. And when it comes to unveiling parts of the periodic table yet undiscovered, ORNL is doing some heavy lifting.

Ashleigh Kimberlin and Mikayla Molnar achieve success with a gas-trapping apparatus for Ac-225 production. Credit: ORNL, U.S. Dept. of Energy

In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.

Former ORNL Director Thom Mason presents Tom Kollie with a National Intelligence Meritorious Unit Citation on behalf of James Clapper, former director of national intelligence, and the national intelligence community in June 2017. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

A 25-year career with the U.S. Navy, commanding combat missions overseas, brought Tom Kollie back to where he came from — ready to serve his country in a new way.

 

Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.

As a medical isotope, thorium-228 has a lot of potential — and 91°µÍø produces a lot.

Initially, Kevin Gaddis’s adapted HPIC will be used only for the fourth of six separations in  actinium-225 processing, but he hopes it will later be used for other separations — and other isotopes. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

An 91°µÍø researcher has invented a version of an isotope-separating device that can withstand extreme environments, including radiation and chemical solvents.

Balendra Sutharshan

In the mid-1980s, Balendra Sutharshan moved to Canada from the island nation of Sri Lanka. That move set Sutharshan on a path that had him heading continent-spanning collaborations and holding leadership posts at multiple Department of Energy

Brenda Smith, shown here working with a gas viscometer in her research lab, is one of several people concurrently researching the thermophysical properties of feedstock gas. Their research will support computational researchers who are designing processes to separate isotopes. Credit: Carlos Jones/ORNL, US Dept. of Energy

For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at 91°µÍø.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.